Complement C3 and C-reactive protein in male survivors of myocardial infarction

Atherosclerosis

Volumn 203, Issue 2, 2009, Pages 538-543

  Carter, Angela M ^a   Prasad, Usha K ^a   Grant, Peter J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

C reactive protein; Complement C3; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVOR;

AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; COMPLEMENT C3; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFLAMMATION; MALE; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RISK FACTORS; ROC CURVE; TREATMENT OUTCOME;

EID: 62649145947     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.07.007     Document Type: Article

References (28)

1. Carter A.M. Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res 2 (2005) 113-121
2. Ridker P.M., Wilson P.W., and Grundy S.M. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation 109 (2004) 2818-2825
3. Pepys M.B., and Hirschfield G.M. C-reactive protein: a critical update. J Clin Invest 111 (2003) 1805-1812
4. Mold C., Gewurz H., and Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 42 (1999) 23-30
5. Walport M.J. Complement: first of two parts. N Engl J Med 344 (2001) 1058-1066
6. Muscari A., Bozzoli C., Puddu G.M., et al. Association of serum C3 levels with the risk of myocardial infarction. Am J Med 98 (1995) 357-364
7. Szeplaki G., Prohaszka Z., Duba J., et al. Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women. Atherosclerosis 177 (2004) 383-389
8. Engstrom G., Hedblad B., Janzon L., and Lindgarde F. Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur J Cardiovasc Prev Rehabil 14 (2007) 392-397
9. Muscari A., Massarelli G., Bastagli L., et al. Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men. Eur Heart J 21 (2000) 1081-1090
10. Ajjan R., Grant P.J., Futers T.S., et al. Complement C3 and C-reactive protein levels in patients with stable coronary artery disease. Thromb Haemost 94 (2005) 1048-1053
11. Halkes C.J., van Dijk H., de Jaegere P.P., et al. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arterioscler Thromb Vasc Biol 21 (2001) 1526-1530
12. Engstrom G., Hedblad B., Eriksson K.F., Janzon L., and Lindgarde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 54 (2005) 570-575
13. Onat A., Uzunlar B., Hergenc G., et al. Cross-sectional study of complement C3 as a coronary risk factor among men and women. Clin Sci (Lond) 108 (2005) 129-135
14. Szeplaki G., Varga L., Laki J., et al. Elevated complement C3 is associated with early restenosis after eversion carotid endarterectomy. Thromb Haemost 96 (2006) 529-534
15. Sparrow C.P., Burton C.A., Hernandez M., et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 21 (2001) 115-121
16. Patel T.N., Shishehbor M.H., and Bhatt D.L. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J 28 (2007) 664-672
17. Muscari A., Bastagi L., Poggiopollini G., et al. Short term effect of atorvastatin and vitamin E on serum levels of C3, a sensitive marker of the risk of myocardial infarction in men. Cardiovasc Drugs Ther 15 (2001) 453-458
18. Verseyden C., Meijssen S., van Dijk H., Jansen H., and Castro CM. Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia. J Lipid Res 44 (2003) 2100-2108
19. Choy L.N., Rosen B.S., and Spiegelman B.M. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 267 (1992) 12736-12741
20. Engstrom G., Hedblad B., Janzon L., and Lindgarde F. Weight gain in relation to plasma levels of complement factor 3: results from a population-based cohort study. Diabetologia 48 (2005) 2525-2531
21. Muscari A., Sbano D., Bastagli L., et al. Effects of weight loss and risk factor treatment in subjects with elevated serum C3, an inflammatory predictor of myocardial infarction. Int J Cardiol 100 (2005) 217-223
22. Cianflone K., Maslowska M., and Sniderman A.D. Acylation stimulating protein (ASP), an adipocyte autocrine: new directions. Semin Cell Dev Biol 10 (1999) 31-41
23. Mak T.W., and Saunders M.E. The immune response: basic and clinical principles (2006), Elsevier Academic Press, Oxford
24. Laine P., Pentikainen M.O., Wurzner R., et al. Evidence for complement activation in ruptured coronary plaques in acute myocardial infarction. Am J Cardiol 90 (2002) 404-408
25. Torzewski M., Klouche M., Hock J., et al. Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 18 (1998) 369-378
26. Meuwissen M., van der Wal A.C., Niessen H.W., et al. Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J Clin Pathol 59 (2006) 196-201
27. Tedesco F., Fischetti F., Pausa M., et al. Complement-endothelial cell interactions: pathophysiological implications. Mol Immunol 36 (1999) 261-268
28. Ando B., Wiedmer T., Hamilton K.K., and Sims P.J. Complement proteins C5b-9 initiate secretion of platelet storage granules without increased binding of fibrinogen or von Willebrand factor to newly expressed cell surface GPIIb-IIIa. J Biol Chem 263 (1988) 11907-11914